Start with the research question
Is the study measuring concentrations in blood, a particular biomarker or a clinical outcome? These are different questions. Higher exposure in a pharmacokinetic study does not, by itself, mean a proportional increase in clinical benefit.
Human studies, laboratory experiments and animal studies also provide different kinds of evidence. A technical presentation should identify the evidence type and show the full study reference alongside the result.
Source: EMA / ICH M13A (2024) — Methodological reference for AUC and Cmax; Purpura et al. (2024) — Randomised crossover vitamin C study
The main measures on the chart
| Measure | What it describes | What to check |
|---|---|---|
| AUC | Area under the concentration–time curve over a specified interval | The same analyte, sampling interval and units. |
| Cmax | Highest measured concentration | Sampling schedule and baseline treatment. |
| Tmax | Time to the highest concentration | Do not treat it alone as evidence of greater efficacy. |
| Clinical endpoint | A predefined clinical outcome | It is distinct from pharmacokinetic measurements. |
Source: EMA / ICH M13A (2024) — Methodological reference for AUC and Cmax
Why dose and comparator matter
Capsule weight, total formulation weight including carriers, and active amount describe different quantities. A comparison table should record them separately. Dividing results from separate studies using different doses does not establish a valid absorption multiple.
A claim of “the same effect at a lower dose” requires appropriate research directly comparing the relevant doses and outcome. A study measuring blood concentrations does not automatically establish dose equivalence for a different clinical objective.
Source: EMA / ICH M13A (2024) — Methodological reference for AUC and Cmax
Make the design visible
A 2024 vitamin C study used a randomised, double-blind, placebo-controlled crossover design in 27 participants. It illustrates why the comparator and study design should be presented with the findings.
A 2018 liposomal glutathione study, in contrast, was a one-month pilot involving 12 people. Its lack of a placebo group and small sample affect interpretation. Publication does not remove those design limitations.
Source: Purpura et al. (2024) — Randomised crossover vitamin C study; Sinha et al. (2018) — Liposomal glutathione pilot study
A short record for your technical dossier
When assessing an ingredient with Biontera, consider the manufacturer’s research alongside the identity and specification of the material being offered. A concise evidence record helps procurement and formulation teams work from the same information.
- Tested commercial formulation, manufacturer and composition.
- Participant number, design, duration and feeding conditions.
- Active dose, comparator and primary outcome.
- Uncertainty in the results, funding disclosure and relevance to the intended formula.